Rona Therapeutics Shares RN0361 Phase 1 Data at American Heart Association 2025
November 10, 2025
Rona Therapeutics, a global pioneer in RNAi-based therapies, revealed key Phase 1 findings for RN0361, a long-acting siRNA that targets Apolipoprotein C3 (ApoC3). The data,